Aclaris Therapeutics, Inc.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases. Its core engine is the KINect drug discovery platform, which it uses to generate product candidates with differentiated target affinity, specificity, and potency. The company is still in development mode and does not have commercial product sales from its own pipeline; instead, it seeks partnerships and other transactions to advance, approve, and potentially commercialize its assets. Aclaris also earns revenue from contract research services and from licensing arrangements tied to partnered assets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical and preclinical drug candidates for immuno-inflammatory diseases, including antibodies and small molecules.
Laboratory services provided to third parties using the company’s research and development capabilities.
Upfront, milestone, and royalty income from out-licensed assets and collaboration agreements.
Products
Reported · share of revenue- License and Service76.1 %
- Laboratory Research Revenue23.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Aclaris’s primary customers are not end patients today, but pharmaceutical and biotechnology partners that license or co-develop its assets. These partners buy access to Aclaris’s intellectual property, preclinical/clinical data, and development rights because the company is trying to monetize programs before full commercialization. A second customer group is third-party clients that use its contract research laboratory services, which are supported by Aclaris’s early-stage R&D expertise. In the future, if any product reaches market, the end customers would be physicians, payors, and patients in immunology and dermatology markets, but that is not yet the company’s main revenue base.
License or co-develop bosakitug, ATI-052, lepzacitinib, and other assets to gain access to differentiated immunology programs and development rights.
Purchase laboratory and research services because Aclaris can monetize its scientific capabilities while its internal pipeline remains pre-commercial.
Physicians, payors, and patients would be the eventual buyers of approved therapies, especially in dermatology and immuno-inflammatory indications.
Strategy
Aclaris is focused on advancing a pipeline of immuno-inflammatory therapies while preserving capital through partnerships and external development options. The company is prioritizing bosakitug, ATI-052, and other candidates that could be developed either internally or with third-party partners, which reduces the need to fund every program alone. It is also trying to monetize in-licensed assets such as the Sun Pharma and Pediatrix arrangements through milestones and royalties. Because the company remains clinical-stage and loss-making, securing non-dilutive funding and strategic transactions is central to extending runway and improving the odds of eventual commercialization.
Aclaris needs external capital and commercialization capability to move programs forward without bearing the full cost alone.
Clinical progress is necessary to create partnering value and eventual approval potential.
The company expects continued operating losses and needs funding to sustain R&D.
Geography
Aclaris is headquartered in the United States and conducts its core research and corporate activities there. The company does not have manufacturing facilities, so clinical and preclinical supply production is outsourced to third parties rather than tied to a specific internal manufacturing geography. Its partnering footprint is international, including Greater China through the Pediatrix license for lepzacitinib and global partnering ambitions for other programs. Geography matters mainly through licensing territories, regulatory pathways, and the location of third-party development and manufacturing partners rather than through owned physical operations.
Risks
Aclaris faces the classic risks of a clinical-stage biotech company: high R&D burn, uncertain clinical outcomes, and dependence on external financing. Its programs rely heavily on third-party data, CROs, and contract manufacturers, so any data integrity issue, protocol failure, or supply disruption could delay development or damage regulatory prospects. The company also faces intense competition from larger pharmaceutical and biotech firms developing similar TSLP- and cytokine-targeting therapies, which raises the risk that a competitor reaches market first or with a better profile. In addition, because future value depends on partnerships and licensing economics, weak deal execution, reimbursement pressure, or adverse safety findings could materially reduce the commercial attractiveness of its assets.
- Financing and dilution riskImpact: HighLikelihood: High
The company expects continued losses and will need additional capital or partnering proceeds to sustain development.
Exposure: Corporate funding and pipeline advancement
- Clinical development failureImpact: HighLikelihood: Medium
Pipeline value depends on positive trial outcomes, but immunology programs can fail on efficacy, safety, or endpoint design.
Exposure - Dependence on third-party data and partnersImpact: HighLikelihood: Medium
Aclaris in-licenses assets and relies on external parties for trials, manufacturing, and some commercialization activities, so errors outside its control can impair programs.
Exposure - Manufacturing and supply chain dependenceImpact: MediumLikelihood: Medium
The company has no manufacturing facilities and depends on third parties for clinical and preclinical supply.
Exposure: All product candidates
- Competitive pressure in immunologyImpact: Medium
Large pharma and biotech competitors are developing similar TSLP and cytokine-pathway therapies, which can reduce market opportunity and partnering leverage.
Exposure
Accounting
Judgemental itemsUpfront, regulatory, and commercial milestones from Sun Pharma and Pediatrix can make revenue highly uneven and dependent on contract events.
Impact: Affects reported revenue timing and comparability across periods
Laboratory services revenue depends on hours billed and service delivery, which can fluctuate with client demand.
Impact: Drives volatility in the contract research segment
Royalty proceeds sold to OMERS are recognized under a units-of-revenue method, which can decouple accounting income from cash receipts.
Impact: Affects other income and earnings quality
Acquired or in-licensed assets and related obligations require judgment in valuation and expense recognition.
Impact: Can materially affect R&D expense and balance sheet estimates
Similar listed companies
Publicly listed companies with a comparable business focus.
Nektar Therapeutics
NKTR · Pharmaceutical Preparations
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Acrivon Therapeutics, Inc.
ACRV · Pharmaceutical Preparations
Kezar Life Sciences, Inc.
KZR · Pharmaceutical Preparations
Kiniksa Pharmaceuticals International, plc
KNSA · Pharmaceutical Preparations
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical…
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Last updated: 24/09/2026